ArticleVeterinary research communications2025
Monoclonal antibody based competitive 3AB non-structural protein ELISA for detection of foot-and-mouth disease virus infection.
Article in Veterinary research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Foot and mouth disease (FMD) is one of the most infectious viral diseases of cloven-footed animals which cause devastating global economic losses. FMD virus (FMDV) specific non-structural protein (NSP) antibodies are indicative of a current or past infection with any of the seven FMDV serotypes(O, A, C, Asia1, SAT1, SAT2, SAT3). In the present study, a monoclonal antibody (MAb) was developed against recombinant FMDV NSP 3AB3 (r3AB3) via hybridoma system and applied in a competitive enzyme linked immunosorbent assay (cELISA) for NSP antibody detection. The newly generated MAb #FMDV3AB-2E4 was identified as an IgG1 isotype that specifically binds to NSP 3B. A cELISA termed FMDV3AB-2E4 cELISA was developed using r3AB3 as the antigen and the MAb. Percent inhibition (PI) cut-off of the cELISA was determined by receiver operating characteristics curve analysis of 202 known FMDV-positive and 730 negative serum samples from multiple species (cattle, buffalo sheep, goat, pig and deer). At the selected cut-off value of 45 PI the cELISA exhibited diagnostic sensitivity (DSn) of 95.54% and diagnostic specificity (DSp) of 98.36% at 95% confidence interval. Compared to commercial PrioCHECK FMD NS test the DSn was 93.54% and DSp was 97.46% for bovine and caprine sera (n = 446) obtained from naïve, FMDV-infected and vaccinated animals. Concordance rate of new cELISA and extensively used in-house r3AB3 indirect ELISA was 96.61% for test results of 3016 cattle sera collected across multi-locations in India. The species independent NSP antibody test developed would be a useful tool in FMD control efforts in India and other countries.
Indexed as
Identifiers
40381052What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.